What is Microbion?
Headquartered in Bozeman, Montana, and founded in 2000, Microbion operates at the intersection of advanced microbiology and pharmacology. The company specializes in the development of novel microbial bioenergetic inhibitors, a therapeutic class designed to disrupt the metabolic processes of pathogens that have become resistant to conventional antibiotics. By targeting the fundamental energy production mechanisms of bacteria, Microbion offers a differentiated strategy for treating difficult-to-manage infections that currently lack effective clinical solutions. Its market position is bolstered by a robust intellectual property portfolio and strategic partnerships with organizations dedicated to combating antibiotic resistance.
How much funding has Microbion raised?
Microbion has raised a total of $46.5M across 6 funding rounds:
Private Equity
$932K
Private Equity
$1.2M
Unspecified
$100K
Private Equity
$25M
Other Financing Round
$17.1M
Private Equity
$2.1M
Private Equity (2010): $932K, investors not publicly disclosed
Private Equity (2012): $1.2M, investors not publicly disclosed
Unspecified (2014): $100K supported by Undisclosed
Private Equity (2016): $25M featuring GF Securities and Quark Venture
Other Financing Round (2020): $17.1M backed by Carb-X and Cystic Fibrosis Foundation
Private Equity (2022): $2.1M with participation from MTEC companies
Key Investors in Microbion
MTEC companies
MTEC is a consortium dedicated to advancing medical innovation by facilitating the rapid deployment of technologies that enhance the health of military personnel and civilians through collaborative funding and resource sharing.
Carb-X
CARB-X is a global non-profit partnership that accelerates antibacterial innovation by providing critical funding and support for early-stage development of life-saving products to combat drug-resistant bacteria.
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a leading non-profit organization focused on funding research and development to find a cure for cystic fibrosis and improve the quality of life for those affected by the disease.
What's next for Microbion?
With the successful closure of this major strategic investment, Microbion is well-positioned to transition its lead programs into advanced clinical trials. The company's strategic roadmap focuses on expanding its therapeutic reach, particularly in addressing infections that pose the highest risk to public health. Future efforts will likely prioritize the optimization of its bioenergetic inhibitor platform and the strengthening of its regulatory filings. As the firm moves deeper into the clinical-stage lifecycle, the focus will shift toward demonstrating efficacy in human trials, thereby unlocking significant value for stakeholders and providing essential new tools for the global medical community to combat the rising tide of antimicrobial resistance.
See full Microbion company page
